國家衛生研究院 NHRI:Item 3990099045/3101

NHRI > National Institute of Cancer Research > Jacqueline Whang-Peng(1996-2007) > Periodical Articles > Item 3990099045/3101

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/3101

Title:	Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma
Authors:	Yuan, JN;Chao, Y;Lee, WP;Li, CP;Lee, RC;Chang, FY;Yen, SH;Lee, SD;Whang-Peng, J
Contributors:	National Institute of Cancer Research
Abstract:	Background To investigate the therapeutic index of combining etoposide, doxorubicin (adriamycin), cisplatin, 5-fluorouracil (5-FU), and leucovorin (EAPFL) chemotherapy in the treatment of advanced HCC, a trial of a novel schedule of triweekly administration was conducted. Patients and methods Sixty-six patients with measurable advanced HCC, adequate liver and renal functions and adequate bone marrow reserves in whom local treatment was not indicated were studied. Triweekly EAPFL treatment consisted of a concomitant boost of etoposide 40 mg/m(2) i.v. over 30 min on day 1, 2, and 3, doxorubicin 30 mg/m(2) i.v. over 30 min on day 1 to a backbone regimen, triweekly PFL chemotherapy with cisplatin 60 mg/m(2), 5-FU 1,200 mg/m(2), and leucovorin 120 mg/m(2) given simultaneously by a 72-h i.v. infusion. Response, survival, and toxicity were evaluated. Results One patient had complete response (1%) and thirteen patients had partial response (20%). The objective response rate was 21% (95% confidence interval 11-31%). The median overall survival and median time to progression were 8.9 months and 3.3 months, respectively. Major treatment toxicities (grade 3-4) were neutropenia (28%), anemia (11%), thrombocytopenia (7%), hepatotoxicity (5%), vomiting (2%), and diarrhea (2%). There was no treatment-related death. Conclusion Triweekly EAPFL chemotherapy is a moderately effective regimen with tolerable toxicities in the treatment of advanced HCC.
Keywords:	Oncology
Date:	2008-06
Relation:	Medical Oncology. 2008 Jun;25(2):201-206.
Link to:	http://dx.doi.org/10.1007/s12032-007-9013-3
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1357-0560&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000256028700014
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=48049120897
Appears in Collections:	[Jacqueline Whang-Peng(1996-2007)] Periodical Articles

Files in This Item:

File	Description	Size	Format
ISI000256028700014.pdf		162Kb	Adobe PDF	696	View/Open

Loading...